Amgen to expand Ohio biotech manufacturing plant

Deena Beasley

Fri, Apr 25, 2025, 10:12 AM 1 min read

By Deena Beasley

(Reuters) -Amgen connected Friday announced a $900 cardinal enlargement of its Ohio biotech manufacturing facility, becoming the latest successful a drawstring of drugmakers pledging to summation U.S. capableness amid Trump medication threats of imaginable import tariffs.

Amgen, based successful Thousand Oaks, California, said the plans bring its full concern successful cardinal Ohio to much than $1.4 billion, creating 750 jobs.

Other drugmakers committing precocious to U.S. manufacturing expansions see Eli Lilly, Novartis, Roche, and Johnson & Johnson.

Pharmaceutical Research and Manufacturers of America, the industry's commercialized group, has said it tin instrumentality 5 to 10 years and $2 cardinal to motorboat a caller U.S. accumulation installation successful portion due to the fact that of regulatory requirements. A survey commissioned by the lobbying radical recovered that tariffs could pb to higher cause prices.

U.S. President Donald Trump's medication has opened a nationalist information probe into pharmaceuticals successful a bid to show wherefore the U.S. needs tariffs to boost home manufacturing. Rates and timing stay uncertain, but the manufacture has been lobbying for phased-in tariffs.

Amgen said that since transition of the Tax Cuts and Jobs Act of 2017 it has invested astir $5 cardinal successful U.S. superior expenditures, generating further downstream output to the U.S. system of astir $12 billion.

The biotechnology institution announced successful December plans to put $1 cardinal to physique a 2nd cause substance manufacturing works successful Holly Springs, North Carolina. Amgen besides has manufacturing facilities successful Massachusetts, Rhode Island, California and Puerto Rico.

Outside of the United States, Amgen's manufacturing operations are successful Ireland, the Netherlands and Singapore.

(Reporting By Deena Beasley; Editing by Hugh Lawson)